Terumo Neuro
Michelle Wetherby currently serves as the Director of Clinical Research and Operations at Terumo Neuro and holds a position as an Adjunct Professor in the Applied Clinical Research Graduate Program at St. Cloud State University. With extensive experience in clinical research, Michelle has previously held roles such as Director of Clinical Research at Tactile Medical, Director of Global Clinical Trial Support Services at Boston Scientific, and Associate Director of Global Clinical Operations at Abbott. Michelle's career includes positions at St. Jude Medical, Independent consulting, Myocor, ev3, and Boston Scientific, contributing to expertise in clinical operations and research. Education includes studies at St. Mary's University, University of Phoenix, University of Minnesota, and Hill Murray.
This person is not in any offices
Terumo Neuro
1 followers
A global leader in neurovascular innovation, MicroVention is now Terumo Neuro. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica.